Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Area of Science:

• Oncology
• Dermatology
• Immunotherapy

Background:

• The National Comprehensive Cancer Network (NCCN) Guidelines for Melanoma provide recommendations for cancer treatment.
• Previous guidelines focused on established treatment options for melanoma.
• Significant updates were introduced in the 2016 version.

Purpose of the Study:

• To summarize key changes in the 2016 NCCN Guidelines for Melanoma.
• To highlight new recommendations for adjuvant therapy and in-transit disease.
• To provide an overview of novel treatment options and their supporting evidence.

Main Methods:

• Review of the NCCN Clinical Practice Guidelines in Oncology for Melanoma, specifically the 2016 update.
• Analysis of recommendations for adjuvant therapy and treatment of in-transit melanoma.
• Assessment of newly incorporated treatment modalities and revisions to existing data.

Main Results:

• Adjuvant therapy options expanded to include biochemotherapy and high-dose ipilimumab, based on disease stage.
• Talimogene laherparepvec (T-VEC), an oncolytic immunotherapy, is now recommended for in-transit melanoma.
• Extensive revisions were made to the supporting discussion sections due to new data.

Conclusions:

• The 2016 NCCN Guidelines reflect significant advancements in melanoma treatment.
• New immunotherapy options offer expanded therapeutic strategies for advanced melanoma.
• These updates necessitate a re-evaluation of evidence supporting treatment decisions for melanoma.